The history of electroCore

Co-founded 2005

Co-founded 2005

2005

We were co-founded in 2005 by JP Errico, Thomas J. Errico, MD, former president of the North American Spine Society, Charles Theofilos, MD, and Peter Staats, MD, former president of the North American Neuromodulation Society. The founders shared a mutual belief that neuromodulation represented a tremendous opportunity for safer and more effective treatments across a variety of conditions.

Proof of Concept

Proof of Concept

2006

We ran our first “proof of concept” study, which confirmed our belief that vagus nerve stimulation had the potential to help patients with unmet needs.

Initial Studies

2008

Our first human studies were completed in emergency room patients and tested the ability of VNS to treat asthma.

nVNS Developed

nVNS Developed

2010

We discovered a non-invasive way of delivering VNS therapy, which allowed us to expand beyond acute emergency indications and realize the full breadth of potential of acute and prophylactic nVNS. This breakthrough led to the development of gammaCore.

gammaCore Enters Europe

gammaCore Enters Europe

2011

gammaCore received a CE mark in the European Union for primary headache.

Pivotal Cluster Headache Studies

2014-2015

We completed our first cluster headache study in 2014. Soon after, in 2015, we announced that we would be initiating two pivotal studies in the acute treatment of cluster headache.

FDA Clearance

2017

In April 2017, we received FDA clearance for the acute treatment of pain associated with episodic cluster headache. We began commercial distribution in the US shortly after.

FDA Clearance

2018

In January 2018, we received FDA clearance for the acute treatment of pain associated with migraine headache.

Initial Public Offering

2018

In June 2018, we announced an IPO with the Nasdaq Global Select Market and began trading under ECOR.

FDA Clearance

2018

In November 2018, we received FDA clearance for the adjunctive use for the preventive treatment of cluster headache.